At Initiate, we believe that the key to successful health technology submissions lies in combining strategic foresight with experienced leadership. Our process reduces client effort, maximizes learning retention, and guarantees a consistent high-quality process. This approach was critical in managing complex HTAs across multiple indications, see case study below! Ready to discuss how our tailored solutions can help your submission process? Reach out to hello@initiateconsultancy.com #hta #strategy #oncology
Initiate’s Post
More Relevant Posts
-
Our extensive internal expertise and experience as HTA assessors have enabled us to maintain a 96% success rate in NCPE submissions. This achievement reflects our deep understanding of the health technology assessment landscape and our commitment to delivering high-quality outcomes. As part of our ongoing efforts to share knowledge and best practices, we will be offering an invitation-only HTA training in Ireland before the end of the year. This exclusive event will provide valuable insights into HTA processes and strategies for success in the context of the new era of JCA. If you are interested in attending or would like more information, please feel free to get in touch at hello@initiateconsultancy.com #HTA #NCPE #HealthTechnologyAssessment #Expertise #Training #Ireland #Healthcare
-
Excited to announce that Initiate has launched our Autumn Fitness Challenge! Join us in embracing a healthier lifestyle this season. Let’s get moving together! #FitnessChallenge #HealthyLiving #TeamInitiate #marketaccess
-
-
Initiate are thrilled to be supporting the #RareDiseases2024 campaign from Mediaplanet UK & IE. Learn more about breaking down stigma, increasing understanding and encouraging global collaboration from key thought leaders like Andrew Mumford, CEO, Initiate Consultancy online at Https://tinyurl.com/9hfm7w4t and in today’s The Guardian. Find Initiate on page 4. #RareDiseases2024 #awareness #TheGuardian #
We’re excited to announce the successful launch of our #RareDiseases2024 campaign! 🎉 Available to read within today's The Guardian and online at https://lnkd.in/eTKsifN By raising awareness among the general public, this campaign aimed to help break down stigma, increase understanding, and encourage those who may be affected to seek help. 🧬 We also worked to promote research, advocate for better access to healthcare for individuals with rare diseases, and foster global collaboration between researchers and healthcare professionals. 🌍🤝 Together, we’re making strides toward a future where those impacted by rare diseases have the support and care they need. 💙 #RareDiseases #Healthcare #Research #Collaboration A huge thank you to everyone involved in the campaign: CLINUVEL PHARMACEUTICALS LTD AMICULUM Initiate Alexion Pharmaceuticals, Inc. Medscape Chiesi Group Ipsen BioCryst Pharmaceuticals, Inc. Masters Speciality Pharma Patient Worthy Abzena EURORDIS-Rare Diseases Europe RARE DISEASES INTERNATIONAL Beacon for Rare Diseases Genomics England Genetic Alliance Association of Medical Research Charities
-
Andrew Mumford is attending the 8th Annual Pharma Pricing, Reimbursement & Market Access USA 2024 event, in Philadelphia on the 19th/20th September 2024. Are you attending? Get in touch if you would like to meet up and find out more about how Initiate can support with your pricing, reimbursement and market access projects. #philadelphia #USA #marketaccess #pricing #reimbursement #conference
-
-
We're excited to announce the launch of our brand new website! We've implemented a modern, user-friendly design; uploaded a bank of examples of previous success stories; and added an easy way to see our publications, podcasts, and upcoming conferences and webinars. A big thank you to Geek Designs for helping us to realise our vision! To check it out, visit https://lnkd.in/dqe428Cx. #Marketaccess #HEOR #Newwebsite #Webdesign
-
-
Reach out to our talented Senior Consultant Adelaide Shaw-Maguire whilst at #ESMO2024 to see how we can help you achieve your oncology reimbursement goals! #Marketaccess #HTA #HEOR #Oncology
There is still time to meet and discuss how we at Initiate can support you with your Market Access and HEOR needs whilst at #ESMO2024! Please reach out at a.shaw-maguire@initiateconsultancy.com to arrange your meeting! #marketaccess #HTA #HEOR #Oncology
-
-
Are you attending the ESMO congress? Connect with Adelaide Shaw-Maguire to discuss your oncology project requirements.
We are thrilled to announce our attendance at the ESMO 2024 Congress in Barcelona! This prestigious event brings together the brightest minds in oncology to share ground-breaking research, innovative treatments, and the latest advancements in cancer care. Our team is eager to engage with fellow professionals, exchange ideas, and explore new collaborations. We look forward to contributing to the discussions and learning from the incredible lineup of speakers and sessions. Stay tuned for updates and insights from the congress! Contact Adelaide Shaw-Maguire to arrange a conference meetup to discuss how we can help you achieve successful reimbursement for your oncology products. #ESMO24 #Oncology #Cancer #marketaccess #healtheconomics #conference #reimbursement
-
-
The JCA timeline challenge Companies will need to act decisively and early to fully map and understand market dynamics in the relevant European member states under the new JCA process. With just 90 days to write the submission following receipt of finalised PICOs, poor preparation, and understanding will inevitably hamper the chances of delivering access and increase pressure on those developing the JCA submission. Initiate have developed a methodology that allows us to support our clients ahead of scoping, anticipating possible challenges, reducing the risk of poor preparation, and ensuring submissions have the highest chance of success. The PICO issue For the JCA report to fulfil its objective of accelerating patient access to new treatments across Europe by increasing transparency and reducing duplication of country level HTA, the scoping process will be critical. The starting point for any HTA is defining the PICO: population, intervention, comparators and outcomes. Manufacturers in this process may face several challenges: PICOs may diverge between countries; PICOs requested by member states may not align with available clinical studies; Perceptions of validity of endpoints may differ between member states; Member states may differ in their acceptance of methods of analysing clinical trial data. PICORadar At Initiate we have developed our solution-focused process to support clients initiating their preparations for JCA. The PICORadar builds upon our Reimbursement Radar insight work which tracks HTA outcomes in key markets. Our process builds insight across all member states, developing deep understanding of current modalities and methods of care, validating focus with Payers, and leads our expert team to the development of the minimum number of PICOs, enabling clients to focus on early development of JCA submissions. The PICORadar is a perfect blend of artificial intelligence (AI) for efficient identification of PICO criteria and essential human intelligence (HI) to validate and quality check output. The PICORadar process is designed to support the writing and development of the JCA submission ahead of the scoping to reduce pressure and allow strategic decision making based upon predicting likely PICOs. If you would like to discuss any of the developments outlined above, discover more about PICORadar, or discuss your market access and HEOR needs, please get in touch at hello@initiateconsultancy.com.
-
-
Join Initiate's Andrew Mumford in this Life Science Access Academy masterclass discussing how the Celtic Nations are progressing in the current environment and the prospect of yet more change as fiscal pressures bite. #masterclass #nhsupdate #celticnations
👋Meet our experts:👋 Lynn Harvie Lynn joined the Pharmaceutical Industry in 1998 with Astra Pharmaceuticals, which then went on to become AZ. Following her success in this role, she joined UCB in 2005 within their Established Brands team as a KAM providing Critical Care Solutions across Scotland, Northern Ireland and the North East of England for 10 years. Sarah Jones Sarah has almost 20 years of experience in Life Sciences consultancy. Her specialist skills include all aspects of market research, including pre-licence interactions, advisory boards and payer research. She has specific expertise in the Welsh market access agenda and represents all ABPI member companies on the AWTTC Industry Forum. Andrew Mumford Andrew is a highly experienced global market access expert, leading pragmatic, solution-focused consultancy services at Initiate, a best-in-class consultancy with exceptional experience in the rare disease sector. Eugene Reid Eugene is an experienced Healthcare Development Manager with a demonstrated history of working in the biotechnology industry. He has a strong sales professional background with a Bachelor's degree focused in Applied Biology from Ulster University. #NHS #CelticNations #Healthcare2025 #LSAA #HealthcareStrategies #FiscalPressures #ValueProposition #UKHealthcare #HealthcarePriorities #PrivateSector #HealthPolicy #NHSCommentary #HealthcareOpportunities #HealthcareChallenges #HealthcareInsights #HealthSystemAnalysis #ExpertPanel LSAA Members register here: https://lnkd.in/ebab949y To see our other masterclasses, go to our website: https://lnkd.in/eVJWfGih Can't make the date? Register and we'll send you a link to the recording so you can watch it on demand in your own time.
-
